(NASDAQ: TCRX) Tscan Therapeutics's forecast annual revenue growth rate of 194.21% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.87%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.9%.
Tscan Therapeutics's revenue in 2025 is $4,421,000.On average, 3 Wall Street analysts forecast TCRX's revenue for 2025 to be $547,401,135, with the lowest TCRX revenue forecast at $246,169,227, and the highest TCRX revenue forecast at $848,859,405. On average, 3 Wall Street analysts forecast TCRX's revenue for 2026 to be $728,887,276, with the lowest TCRX revenue forecast at $141,476,568, and the highest TCRX revenue forecast at $1,153,882,885.
In 2027, TCRX is forecast to generate $8,009,780,755 in revenue, with the lowest revenue forecast at $4,054,718,425 and the highest revenue forecast at $11,964,843,085.